Revenio Group Corporation: CE marking for asthma p

Revenio Group Corporation, Stock Exchange Release, January 10, 2017 at 09:00 am

CE MARKING FOR ASTHMA PRODUCT VENTICA® 

A CE marking has been granted for Revenio's asthma product Ventica®. This will enable the sales and marketing of the product, as well as clinical studies of broader scope in Finland and elsewhere in Europe.

Ventica® is designed to assist in the diagnosis of asthma in small children in particular, as well as the evaluation of medication administered during treatment. Measurement of pulmonary function is an important part of treating asthma, but spirometry is unsuitable for children. Asthma symptoms tend to vary on an hourly basis. Ventica measures the patient's expiratory profile during the night, providing doctors with important information on the effectiveness of asthma medication.

"Our development of the asthma product, Ventica, has proceeded according to plan and we have prepared a product for launch on the European markets. We can begin taking the related measures now that we have been awarded a CE marking. We are now in the important stage of obtaining more clinical evidence in support of sales. The rapid product development process and the granting of a CE marking show that our operating model and documentation are in good shape," explains Timo Hildén, President & CEO of Revenio Group.

Revenio Group Corporation

For further information, please contact: Timo Hildén, President & CEO Tel. +358 40 580 4774 timo.hilden@revenio.fi www.revenio.fi www.ventica.fi  

DISTRIBUTION: Nasdaq Helsinki Financial Supervisory Authority (FIN-FSA) Principal media www.revenio.fi

The Revenio Group in brief Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki.